-
Je něco špatně v tomto záznamu ?
Clinical risk stratification: Prague validation of the DAAE score, a clinical tool for estimating risk of disesase progression in multiple sclerosis
JR. Jelgerhuis, T. Uher, EK. Havrdova, D. Horakova, MM. Schoonheim, TA. Fuchs
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, validační studie
- MeSH
- chronicko-progresivní roztroušená skleróza * diagnóza patofyziologie MeSH
- dospělí MeSH
- hodnocení rizik MeSH
- kohortové studie MeSH
- lidé středního věku MeSH
- lidé MeSH
- prognóza MeSH
- progrese nemoci * MeSH
- roztroušená skleróza * diagnóza MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- validační studie MeSH
BACKGROUND: Secondary progressive MS is associated with a worse prognosis, warranting the need for early predictive tools. The DAAE score estimates the five-year risk of transition to clinical diagnosis of SPMS, showing a 38 % risk in high-risk patients in Amsterdam and Buffalo data. The DAAE score remains to be validated against objective disease progression criteria. METHODS: External validation using data from the Prague MS cohort and MSBase-Lorscheider criteria. RESULTS: Among 2022 patients from the Prague MS database, 14.3 % clinically progressed according to MSbase-Lorscheider criteria over five years. Risk increased with higher DAAE scores comparable to the Amsterdam and Buffalo data; secondary validation showed an AUROC of 0.742 with faster progression for higher risk groups (p < 0.05), therapy-adjusted. CONCLUSION: The DAAE score performs similarly between centers and using objective criteria. These validation steps support its use in personalized MS management and treatment.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015485
- 003
- CZ-PrNML
- 005
- 20250731091021.0
- 007
- ta
- 008
- 250708e20250407ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.msard.2025.106423 $2 doi
- 035 __
- $a (PubMed)40222333
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Jelgerhuis, Julia R $u MS Center Amsterdam, Department of Anatomy and Neurosciences, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands
- 245 10
- $a Clinical risk stratification: Prague validation of the DAAE score, a clinical tool for estimating risk of disesase progression in multiple sclerosis / $c JR. Jelgerhuis, T. Uher, EK. Havrdova, D. Horakova, MM. Schoonheim, TA. Fuchs
- 520 9_
- $a BACKGROUND: Secondary progressive MS is associated with a worse prognosis, warranting the need for early predictive tools. The DAAE score estimates the five-year risk of transition to clinical diagnosis of SPMS, showing a 38 % risk in high-risk patients in Amsterdam and Buffalo data. The DAAE score remains to be validated against objective disease progression criteria. METHODS: External validation using data from the Prague MS cohort and MSBase-Lorscheider criteria. RESULTS: Among 2022 patients from the Prague MS database, 14.3 % clinically progressed according to MSbase-Lorscheider criteria over five years. Risk increased with higher DAAE scores comparable to the Amsterdam and Buffalo data; secondary validation showed an AUROC of 0.742 with faster progression for higher risk groups (p < 0.05), therapy-adjusted. CONCLUSION: The DAAE score performs similarly between centers and using objective criteria. These validation steps support its use in personalized MS management and treatment.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a progrese nemoci $7 D018450
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 12
- $a chronicko-progresivní roztroušená skleróza $x diagnóza $x patofyziologie $7 D020528
- 650 12
- $a roztroušená skleróza $x diagnóza $7 D009103
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a kohortové studie $7 D015331
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a validační studie $7 D023361
- 700 1_
- $a Uher, Tomas $u Department of Neurology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Havrdova, Eva Kubala $u Department of Neurology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Horakova, Dana $u Department of Neurology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Schoonheim, Menno M $u MS Center Amsterdam, Department of Anatomy and Neurosciences, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands
- 700 1_
- $a Fuchs, Tom A $u MS Center Amsterdam, Department of Anatomy and Neurosciences, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands. Electronic address: t.fuchs@amsterdamumc.nl
- 773 0_
- $w MED00188780 $t Multiple sclerosis and related disorders $x 2211-0356 $g Roč. 98 (20250407), s. 106423
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40222333 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091016 $b ABA008
- 999 __
- $a ok $b bmc $g 2366368 $s 1252610
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 98 $c - $d 106423 $e 20250407 $i 2211-0356 $m Multiple sclerosis and related disorders $n Mult Scler Relat Disord $x MED00188780
- LZP __
- $a Pubmed-20250708
